In a phase I trial of ex vivo expanded polyclonal recipient Tregs infused into patients receiving living donor kidney transplant, the adoptive transfer of these CD4 iTregs post-transplant was safe with no adverse effects or rejection up to two years post-transplant [58]. The gene discussed is CD4; the disease is urogenital neoplasm.